8. AI in pharma: smarter care, faster outcomes ??

Here at Viz.ai, we’re not just building AI—we’re transforming care pathways to be smarter, faster, and more connected. By seamlessly integrating into clinical workflows, our AI platform enhances diagnostic accuracy and accelerates the connection between patients and the treatments they need. The result? Improved patient outcomes and expanded potential for your therapies.

We’re serious about making a real impact on patients’ lives, with a presence in over 1,700 hospitals, the trust of 50,000+ healthcare professionals, evidence from 100+ clinical studies, partnerships with 10 life sciences companies, and the power of 13 FDA-cleared algorithms.

?? If you’re going to be in San Francisco during the upcoming J.P. 摩根 Healthcare Conference, connect with us to discuss how we can work together to turn AI’s promise into measurable impact—schedule a meeting ??

?? The Latest

Top news at a glance

?? We're collaborating with Microsoft to advance AI-powered clinical workflows. Together, Viz.ai One and Precision Imaging Network, part of Microsoft Cloud for Healthcare, bring more than 48 AI algorithms into clinical workflows, empowering healthcare teams to deliver actionable clinical insights and help improve patient outcomes.

??We're honored to have received the Prix Galien USA 2024 Award for Best Digital Health Solution for our Viz HCM? module. Often referred to as the Nobel Prize of life sciences, the Prix Galien Award is one of the highest accolades in the field, recognizing outstanding innovations that improve human health.

???Viz News

Some recent news highlighting Viz.ai ?

??? We recently announced that we're expanding into lung diseases with new AI-powered software that incorporates natural language processing (NLP) for faster, more accurate diagnosis and follow-up care.

??? Two new studies prove the effectiveness of our AI solutions in detecting cerebral aneurysms and abdominal aortic aneurysms. These studies reaffirm the power of AI to triage and monitor patients and streamline care coordination in clinical practice.

?? Vizion

Industry news on AI and pharma

?? AI is quickly reshaping how care is delivered and experienced. Forbes explores the AI tools making an impact today and what to look out for in the next 2-3 years.

?? Steven Dalvin, MD, MBA , Director of Life Science Innovation at Viz.ai , explores opportunities for AI and digital care coordination in ?? lung diseases, such as COPD, lung cancer, and ILD.

Is pharma designing omnichannel strategies to drive desired HCP behaviors? Christina Kotsi , Director and Medical Lead at 拜耳 , emphasizes, "Pharma must think beyond product promotion and become a trusted partner within health systems so we can support clinical care in real time." Discover insights from pharma leaders at Bayer, Genmab, Novartis, and Novo Nordisk on how omnichannel approaches can drive meaningful impact.

Gil Bashe reflects on 10 transformative examples over the past 5 years that show how AI is enabling healthcare providers to accelerate care delivery, but is only as powerful as its adoption. He makes the case that “AI” in healthcare really means “Augmented Implementation”, where technology and human expertise converge to optimize care delivery.?

??? A recent study published in Nature explored, the role of digital health technologies and AI in transforming the management of cardiovascular diseases. In atherosclerotic cardiovascular disease (ASCVD), AI-assisted algorithms have been approved for assessing risk, particularly through the automatic detection of coronary artery calcium (CAC) using deep learning models. CAC testing is superior to available serum biomarkers and other imaging modalities for ASCVD risk assessment.

?? By the Numbers

We’re highlighting some of our favorite numbers. Our AI technology optimizes the patient care pathway from diagnosis to treatment and empowers HCPs by giving them real-time actionable insights, facilitating informed clinical decision-making, increasing diagnosis, and reducing the time to treatment for more patients who may otherwise go undetected.

Partnering with Viz.ai can enhance life science clinical strategies, ensuring that appropriate treatments reach more patients earlier on their care journey.

??? Events

Our Prix Galien win for Viz HCM? in the Best Digital Health Solution category was one of our proudest achievements this year! Watch our CEO and co-founder, Dr. Chris Mansi, deliver his acceptance speech at the Galien Foundation awards ceremony last week. Chris celebrated the collaborative efforts of both Team Viz and our Pharma partner, whose dedication made the "AI safety net" for patients with Hypertrophic Cardiomyopathy (HCM) a reality.

About Viz.ai

As healthcare’s leading AI platform with 13 FDA-cleared algorithms, Viz.ai is used in over 1,700 hospitals and health systems to analyze medical imaging, EHR data, and more, accelerating diagnosis and treatment. In partnership with pharmaceutical and medical device companies, Viz.ai develops customized solutions for treatable diseases. These solutions are integrated into HCP clinical workflows, empowering HCPs with real-time insights so they can treat more patients and swiftly take the next best clinical action, enhancing adherence to clinical guidelines and advancing patient care. For more information visit Viz.ai/life-sciences.

??? Contributors

Get in touch with Tom Krohn and Sherie Zhou

Between issues, keep current with the latest updates from Viz.ai by following us on LinkedIn and by subscribing to the exclusive email version of Innovizion, sent bi-monthly directly to your inbox from Team Viz.